Metalloproteinases and tissue inhibitors of metalloproteinases

Breast Cancer Research and Treatment

Volumn 52, Issue 1-3, 1998, Pages 113-124

  Toi, Masakazu ^a   Ishigaki, Shinsuke ^a   Tominaga, Takeshi ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

Angiogenesis; Breast cancer; MMP; Prognosis; TIMP

Indexed keywords

MATRIX METALLOPROTEINASE INHIBITOR; METALLOPROTEINASE;

ANGIOGENESIS; BREAST CANCER; CANCER INVASION; DIAGNOSTIC VALUE; EXTRACELLULAR MATRIX; FEMALE; HUMAN; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; REVIEW;

BREAST NEOPLASMS; FEMALE; HUMANS; METALLOENDOPEPTIDASES; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 0032427413     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006167202856     Document Type: Review

References (89)

1. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature (Lond.) 248:67-68, 1980
2. Stetler-Stevenson WG, Liotta LA, Brown PD: Role of type-IV collagenases in human breast cancer. Dickson RB, Lippman ME (eds) Genes, Oncogenes, and Hormones: Advances in Cellular and Molecular Biology of Breast Cancer. Kluwer Academic Publishers, 1991, pp21-41
3. Liotta LA, Thorgeirsson UP, Garbisa S: Role of collagenases in tumor cell invasion. Cancer Metastasis Rev 1:277-288, 1982
4. Liotta LA: Tumor invasion and metastasis - Role of the extracellular matrix. Cancer Res 46:1-7, 1986
5. Tryggvason K, Hoyhtya M, Pyke C: Type IV collagenases in invasive tumors. Breast Cancer Res Treat 24:209-218, 1993
6. Nakajima M, Welch DR, Wynn DM, Tsuruo T, Nicolson GL: Serum and plasma Mr 92,000 progelatinase levels correlate with spontaneous metastasis of rat 13762 NF mammary adenocarcinoma. Cancer Res 53:5802-5807, 1993
7. Folkman J: Angiogenesis in cancer, vascular, rheumatoid, and other diseases. Nature Med 1:27-31, 1995
8. Sava G, Capozzi I, Bergamo A, Gagliardi R, Cocchietto M, Masiero L, Onisto M, Alessio E, Mestroni G, Garbisa S: Down-regulation of tumour gelatinase/inhibitor balance and preservation of tumour endothelium by an anti-metastatic ruthenium complex. Int J Cancer 68:60-66, 1996
9. Plate KH, Breier G, Risau W: Molecular mechanisms of developmental and tumor angiogenesis. Brain Pathol 4:207-218, 1994
10. Azzam HS, Arand G, Lippman ME, Thompson EW: Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. J Natl Cancer Inst 85:1758-1764, 1993
11. Basset P, Wolf C, Rouyer N, Bellocq J-P, Rio M-C, Chambon P: Stromelysin-3 in stromal tissue as a control factor in breast cancer behavior. Cancer 74:1045-1049, 1994
12. Yamagata S, Yoshii Y, Suh JG, Tanaka R, Shimizu S: Occurrence of an active form of gelatinase in human gastric and colorectal carcinoma tissues. Cancer Letters 59:51-55, 1991
13. Brown PD, Bloxidge RE, Stuart NSA, Gatter KC, Carmichael J: Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst 85:574-578, 1993
14. Ochieng J, Fridman R, Nangia-Makker P, Kleiner DE, Liotta LA: Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9. Biochemistry 33:14109-14114, 1994
15. Freije JMP, Diez-Itza I, Balbin M, Sanchez LM, Blasco R, Tolivia J, Lopez-Otin C: Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 269:16766-16773, 1994
16. Wole C, Rouyer N, Lutz Y, Adida C, Loriot M, Bellocq J-P, Chambon P, Basset P: Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc Natl Acad Sci USA 90:1843-1847, 1993
17. Knauper V, Will H, Lopez-Otin C, Smith B, Atkinson SJ, Stanson H, Hembry RM, Murphy G: Cellular mechanisms for human procollagenase-3 (MMP-13) activation. J Biol Chem 271:17124-17131, 1996
18. Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM, Podhajcer OL, Chenard MP, Rio MC, Chambon P: A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 348:699-704, 1990
19. Collier IE, Wilhelm SM, Eisen AZ, Marmer BL, Grant GA, Seltzer JL, Kronberger A, He C, Bauer EA, Goldberg GI: H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J Biol Chem 263:6579-6587, 1988
20. Wilson C, Heppner KJ, Labosky P, Hogan BLM, Matrisian LM: Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci 94:1402-1407, 1997
21. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M: A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370:61-65, 1994
22. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI: Mechanism of cell surface activation of 72-kDa type IV collagenase. J Biol Chem 270:5331-5338, 1995
23. Kinoshita T, Sato H, Takino T, Itoh M, Akizawa T, Seiki M: Processing of a precursor of 72-kilodalton type IV collagenase/gelatinase A by a recombinant membrane-type 1 matrix metalloproteinase. Cancer Res 56:2535-2538, 1996
24. Ohtani H, Motohashi H, Sato H, Seiki M, Nagura H: Dual over-expression pattern of membrane-type metalloproteinase-1 cancer and stromal cells in human gastrointestinal carcinoma revealed by in situ hybridization and immunoelectron microscopy, Int J Cancer 68:565-570, 1996
25. Nomura H, Sato H, Seiki M, Mai M, Okada Y: Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res 55:3263-3266, 1995
26. Tokuraku M, Sato H, Murakami S, Okada Y, Watanabe Y, Seiki M: Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis. Int J Cancer 64:355-359, 1995
27. Tanaka M, Sato H, Takino T, Iwata K, Inoue M, Seiki M: Isolation of a mouse MT2-MMP gene from a lung cDNA library and identification of its product. FEBS Letters 402:219-222, 1997
28. Takino T, Sato H, Shinagawa A, Seiki M: Identification of the second membrane-type matrix metalloproteinase (MT-MMP2) gene from a human placenta cDNA library. J Biol Chem 270:23013-23020, 1995
29. Puente XS, Pendas AM, Llano E, Velasco G, Lopez-Otin C: Molecular cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma. Cancer Res 56:944-949, 1996
30. Ohuchi E, Imai K, Fujii Y, Sato H, Seiki M, Okada Y: Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem 272:2446-2451, 1997
31. Sato H, Kinoshita T, Takino T, Nakayama K, Seiki M: Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2. FEBS Letters 393:101-104, 1996
32. Pei D, Weiss SJ: Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature 375:244-247, 1995
33. Okada A, Bellocq J-P, Rouyer N, Chenard M-P, Rio M-C, Chambon P, Basset P: Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci USA 92:2730-2734, 1995
34. Polette M, Nawrocki B, Gilles C, Sato H, Seiki M, Tournier J-M, Birembaut P: MT-MMP expression and localisation in human lung and breast cancers. Virchows Arch 428:29-35, 1996
35. Ueno H, Nakamura H, Inoue M, Imai K, Noguchi M, Sato H, Seiki M, Okada Y: Expression and tissue localization of membrane types 1,2 and 3 matrix metalloproteinases in human invasive breast carcinoma. Cancer Res 57:2055-2060, 1997
36. Schultz RM, Silberman S, Persky B, Bajkowski AS, Carmichael DF: Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization B16-FI0 melanoma cells. Cancer Res 48:5539-5545, 1988
37. Khokha R, Waterhouse P, Yagel S, Lala PK, Overall CM, Norton G, Denhardt DT: Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. Science (Washington DC) 243:947-950, 1989
38. DeClerck YA, Yean TD, Chan D, Shimada H, Langley KE: Inhibition of tumor invasion of smooth muscle cell layers by recombinant human metalloproteinase inhibitor. Cancer Res 51:2151-2157, 1991
39. Macky AR, Ballin M, Pelina MD, Farina AR, Nason AM, Hartzler JL, Thorgeirsson UP: Effect of phorbol ester and cytokines on matrix metalloproteinase and tissue inhibitor of metalloproteinase expression in tumor and normal cell lines. Invasion Metastasis 12:168-184, 1992
40. Apte S, Olsen BR, Murphy G: The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. J Biol Chem 270:14313-14318, 1995
41. Uria JA, Ferrando AA, Velasco G, Freije JMP, Lopez-Otin C: Structure and expression in breast tumors of human TIMP-3, a new member of the metalloproteinase inhibitor family. Cancer Res 54:2091-2094, 1994
42. Greene J, Wang M, Liu YE, Raymond LA, Rosen C, Shi YE: Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem 271:30375-30380, 1996
43. Abbas Abidi SM, Howard EW, Dmytryk JJ, Pento JT: Differential influence of antiestrogens on the in vitro release of gelatinases (type IV collagenases) by invasive and non-invasive breast cancer cells. Clin Exp Metast 15:432-439, 1997
44. Ree AH, Maelandsmo GM, Fodstad O: Regulation of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in MCF-7 cells: Comparison with regulatory mechanisms of pS2 expression. Clin Exp Metast 14:381-388, 1996
45. Declerck YA, Perez N, Shimada H, Bonne TC, Langley KE, Taylor SM: Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 52:701-708, 1992
46. Wang M, Liu YE, Greene J, Sheng S, Fuchs A, Rosen EM, Shi YE: Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4. Oncogene 14:2767-2774, 1997
47. Sato H, Takono T, Kinoshita T, Imai K, Okada Y, Stetler-Stevenson WG, Seiki M: Cell sarface binding and activation of gelatinase A induced by expression of membrane-type-1-matrix metalloproteinase (MT1-MMP). FEBS Lett 385:238-240, 1996
48. Hahnel E, Harvey JM, Joyce R, Robbins PD, Sterrett GF, Hahnel R: Stromelysin-3 expression in breast cancer biopsies: Clinico-pathological correlations. Int J Cancer 55:771-774, 1993
49. Polette M, Clavel C, Cockett M, de Bentzmann SG, Murphy G, Birembaut P: Detection and localization of mRNAs encoding matrix metalloproteinases and their tissue inhibitor in human breast pathology. Invasion Metast 13:31-37, 1993
50. Kossakowska AE, Huchcroft SA, Urbanski SJ, Edwards DR: Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans. Br J Cancer 73:1401-1408, 1996
51. Davies B, Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR: Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 67:1126-1131, 1993
52. Onisto M, Riccio MP, Scannapieco P, Caenazzo C, Griggio L, Spina M, Stetler-Stevenson WG, Garbisa S: Gelatinase A/ TIMP-2 imbalance in lymph-node-positive breast carcinomas, as measured by RT-PCR. Int J Cancer 63:621-626, 1995
53. Duffy MJ, Blaser J, Duggan C, McDermott E, O'Higgins N, Fennelly JJ, Tschesche H: Assay of matrix metalloproteases types 8 and 9 by ELISA in human breast cancer. Br J Cancer 71:1025-1028, 1995
54. Johnatty R, Taub D, Reeder S, Turcovski-Corrales SM, Cottam DW, Stephenson TJ, Rees RC: Cytokine and chemokine regulation of pro MMP-9 and TIMP-1 production by human peripheral blood lymphocytes. J Immunol 158:2327-2333, 1997
55. Himelstein BP, Muschel RJ: Induction of matrix metalloproteinase 9 expression in breast carcinoma cells by a soluble factor from fibroblasts. Clin Exp Metast 14:197-208, 1996
56. Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH: Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 149:273-282, 1996
57. Polette M, Clavel C, Cockett M, de Bentzmann SG, Murphy G, Birembaut P: Detection and localization of mRNAs encoding matrix metalloproteinases and their tissue inhibitor in human breast pathology. Invasion Metast 13:31-37,1993
58. Poulsom R, Hanby AM, Pignatelli M, Jeffery RE, Longcroft JM, Rogers L, Stamp GWH: Expression of gelatinase A and TIMP-2 mRNAs in desmoplastic fibroblasts in both mammary carcinomas and basal cell carcinomas of the skin. J Clin Pathol 46:429-436, 1993
59. Polete M, Gilbert N, Stas I, Nawrocki B, Nobel A, Remacle A, Stetler-Stevenson WG, Birembaut P, Foidart J-M: Gelatinase A expression and localization in human breast cancers. An in situ hybridization study and immunohistochemical detection using confocal microscopy. Virchows Archiv 424:641-645, 1994
60. Engel G, Heselmeyer K, Auer G, Backdahl M, Eriksson E, Linder S: Correlation between stromelysin-3 mRNA level and outcome of human breast cancer. Int J Cancer 58:830-835, 1994
61. Byrne JA, Tomasetto C, Rouyer N, Bellocq JP, Rio MC, Basset P: The tissue inhibitor of metalloproteinases-3 gene in breast carcinoma: Identification of multiple polyadenylation sites and a stromal pattern of expression. Mol Med 1:418-427, 1995
62. Lindsay CK, Thorgeirsson UP, Tsuda H, Hirohashi S: Expression of tissue inhibitor of metalloproteinase-1 and type IV collagenase/gelatinase messenger RNAs in human breast cancer. Human Pathol 28:359-366, 1997
63. Monteagudo C, Merino MJ, San-Juan J, Liotta LA, Stetler-Stevenson WG: Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue. Am J Pathol 136:585-592, 1990
64. Clavel C, Polette M, Doco M, Binninger I, Birembaut P: Immunolocalization of matrix metallo-proteinases and their tissue inhibitor in human mammary pathology. Bull Cancer 79:261-270, 1992
65. Hoyhtya M, Fridman R, Komarek D, Porter-Jordan K, Stetler-Stevenson WG, Liotta LA, Liang C-M: Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies. Int J Cancer 56:500-505, 1994
66. Iwata H, Kobayashi S, Iwase H, Masaoka A, Fujimoto N, Okada Y: Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas. Jpn J Cancer Res 87:602-611, 1996
67. Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Kramer MD, Janicke F, Klijn JGM: Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12:1648-1658, 1994
68. Grondahl-Hansen J, Christensen IJ, Briand P, Pappot H, Mouridsen HT, Blichert-Toft M, Dano K, Brunner N: Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients. Clin Cancer Res 3:233-239, 1997
69. Grignon DJ, Sakr W, Toth M, Ravery V, Angulo J, Shamsa F, Pontes JE, Crissman JC, Fridman R: High level of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res 56:1654-1659, 1996
70. Mori M, Mimori K, Shiraishi T, Fujie K, Baba K, Kusumoto H, Haraguchi M, Ueno H, Akiyoshi T: Analysis of MT1-MMP and MMP2 expression in human gastric cancers. Int J Cancer 74:316-321, 1997
71. Gasparini G, Harris AL: Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool. J Clin Oncol 13:765-782, 1995
72. Johnson MD, Kim HC, Chesler L, Tsao-Wu G, Bouck N, Polverini PJ: Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol 160:194-202, 1994
73. Murphy AN, Unsworth EJ, Stetler-Stevenson WG: Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 157:351-358, 1993
74. Toi M, Taniguchi T, Yamamoto Y, Kurizaki T, Suzuki H, Tominaga T: Clinical significance of the determination of angiogenic factors. Eur J Cancer 32A:2513-2519, 1996
75. Eda H, Fujimoto K, Watanabe S, Ura M, Hino A, Tanaka Y, Wada K, Ishitsuka H: Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluoro-uridine. Cancer Chem Pharm 32:333-338, 1993
76. Folkman J: What is the role of thymidine phosphorylase in tumor angiogenesis? J Natl Cancer Inst 88:1091-1092, 1996
77. Ferrara N: Vascular endothelial growth factor. Eur J Cancer 32A:2413-2422, 1996
78. Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, Matsubara I, Vinante O, Bonoldi E, Boracchi P, Gatti C, Suzuki H, Tominaga T: Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89:139-147, 1997
79. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL: Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 56:4625-4629, 1996
80. Ito A, Nakajima S, Sasaguri Y, Nagase H, Mori Y: Co-culture of human breast adenocarcinoma MCF-7 cells and human dermal fibroblasts enhances the production of matrix metalloproteinases 1, 2 and 3 in fibroblasts. Br J Cancer 71:1039-1045, 1995
81. Kondapaka SB, Fridman R, Reddy KB: Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. Int J Cancer 70:722-726, 1997
82. Klijn JGM, Berns PMJJ, Schmitz PIM, Foekens JA: The clinical significance of epidermal growth factor receptor (EGFR) in human breast cancer: A review on 5232 patients. Endocr Rev 13:3-17, 1992
83. Griffiths L, Dachs GU, Bicknell R, et al: The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor / thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo. Cancer Res 57:570-572, 1997
84. Clauss M, Gerlach M, Gerlach H, Brett J, Wanf F, Familletti PC, Pan Y-C, Olander JV, Connolly DT, Stern D: Vascular permeability factor. A tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 172:1535-1545, 1990
85. Gabrilovich DI, Chen HL, Girgis KR, Cunningham T, Meny GM, Nadaf S, Kavanaugh D, Carbone D: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Med 2:1096-1103, 1996
86. Kuwabara K, Ogawa S, Matsumoto M, Koga S, Clauss M, Pinsky D, Lyn P, Leavy J, Witte L, Joseph-Silverstein J, Furie M, Torcia G, Cozzolino F, Kamada K, Stern D: Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells. Proc Natl Acad Sci 92:4606-4610, 1995
87. Sledge GW Jr, Qulali M, Goulet R, Bone EA, Fife R: Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst 87:1546-1550, 1995
88. Talbot DC, Brown PD: Experimental and clinical studies on the use of matrix metalloproteinase inhibitots for the treatment of cancer. Eur J Cancer 32A:2528-2533, 1996
89. Anderson IC, Shipp MA, Docherty AJP, Teicher BA: Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res 56:715-718, 1996